Innoviva, Inc. (INVA)
收市後：
Innoviva, Inc.
1350 Old Bayshore Highway
Suite 400
Burlingame, CA 94010
United States
650 238 9600
https://www.inva.com
版塊: Healthcare
行業: Biotechnology
全職員工: 112
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Pavel Raifeld C.F.A. | Chief Executive Officer | 754.67k | 無 | 1984 |
| Ms. Marianne Zhen CPA | Chief Accounting Officer & Secretary | 530.21k | 無 | 1969 |
| Mr. Stephen Basso M.B.A. | Chief Financial Officer | 無 | 無 | 1966 |
描述
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
公司管治
截至 2024年4月1日 止，Innoviva, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：9；董事會：9；股東權利：4；現金賠償：5。
